Driving clarity
in clinical development

Talk to us about where your study is today

Every clinical trial is a chain of high-stakes decisions.

Unlearn can help at any point in your study. Digital twins, data, and AI strengthen each one — so trial teams can commit with confidence, and evidence compounds from one decision to the next.

Explore every entry point

AI Regulatory Strategy Expertise

READOUT INFORMS THE NEXT DESIGN

Sample size reduction
locked into study design

Total cost savings for a Phase 1/2 study

Pressure-test your design ↗

Control Arm size reduction*

Enrollment time saved (months)*

*Approximate values

View AbbView Case Study ↗

A completed Phase 3 ALS trial, re-analyzed with digital twins

In a re-analysis of a completed Phase 3 ALS trial, incorporating participants' digital twins reduced outcome variance by 18% and enrollment by 92 fewer participants.

Unlock more from your data ↗

Fewer participants

Lower cost

Why leading sponsors choose Unlearn

“Working with Unlearn to mine their extensive, well-curated database through the use of the ALS DTG will enable us to explore smarter designs and make confident and informed decisions as we plan our Phase 1/2 trial. Ultimately, these insights can help us to move faster for people living with ALS who are waiting for new treatment options."

Eric Green, M.D., Ph.D., co-founder and CEO of Trace Neuroscience

See Press Release

“The ecosystem at the moment doesn’t sustain the way we’ve been doing it traditionally. And (Unlearn) is at the leading edge of this thinking.”

Kasper Roet, founder and CEO of QurAlis

View Presentation

"The collaboration with Unlearn and the resulting data further increases our confidence in our pioneering approach towards achieving symptomatic relief and disease modification in Alzheimer’s. This will support our efforts to advance an optimized second-generation therapy. Digital twins offer a new lens for interpreting biomarker trends over time—especially in early-stage trials where every data point matters."

Gerard Griffioen, Ph.D., CSO of remynd

See Press Release